 Home > Medical News > Medicines Company News > WuXi Biologics and Hequan Pharmaceuticals establish a joint venture company WuXi Helian focuses on integrated biologic conjugates CDMO

WuXi Biologics and Hequan Pharmaceuticals establish a joint venture company WuXi Helian focuses on integrated biologic conjugates CDMO

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

iron chemical name

read chemical structures

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

WuXi Biologics, the world's leading open biopharmaceutical technology platform company, and WuXi AppTec subsidiary Hequan Pharmaceuticals today announced the formal establishment of a joint venture, WuXi Helian
.

The company will focus on contract R&D and production services (CDMO) for bio-conjugated drugs such as antibody-conjugated drugs (ADCs), with Dr.

According to the joint venture agreement signed by the two parties, WuXi Biologics and Hequan Pharmaceuticals will each invest US$120 million and US$80 million, respectively, holding 60% and 40% of WuXi Helian's shares
.

WuXi Helian will become a non-wholly-owned subsidiary of WuXi Biologics, providing end-to-end services from antibodies and other conjugated biological drugs, linkers/payloads to biological conjugated drug stock solutions and preparations

"As a rising star that addresses unmet medical needs, bio-conjugated drugs have ushered in vigorous development in recent years
.

We are very pleased to launch WuXi Helian at the right time to strengthen the combined capabilities and scale of WuXi Biologics and Hequan Pharmaceuticals.

Dr.
Chen Minzhang, CEO of Hequan Pharmaceuticals, said: “Many bio-conjugated innovative drug research and development companies often need to cooperate with multiple CDMOs in various aspects such as antibodies, linkers/payloads, biological and chemical couplings, and thus face complex challenges.
Global supply chain and project management challenges
.

In the past few years, we have worked closely with WuXi Biologics in the development of ADCs and various other new bioconjugate drugs, and are committed to providing partners with efficient R&D and production of bioconjugate drugs.

Dr.
Li Jincai, Chief Executive Officer of WuXi
Biologics , said: "I am honored to lead WuXi Biologics.

WuXi Biologics and Hequan Pharmaceuticals will make full use of the leading technology and strong production capacity of WuXi Biologics and Uniquan to create superior bio-conjugated drugs.

Dr.
Li Jincai joined WuXi Biologics in 2011 and has 20 years of biopharmaceutical R&D and industrialization experience, covering process R&D, scale-up and clinical and commercial GMP production
.

During his tenure at WuXi Biologics, Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.